[Form 4] ANI Pharmaceuticals, Inc. Insider Trading Activity
Ori Gutwerg, listed as SVP, Generics at ANI Pharmaceuticals (ANIP), reported a sale of 5,873 shares of ANI common stock on 08/12/2025. The shares were sold in multiple trades at prices ranging from $86.50 to $86.79, with a disclosed weighted average sale price of $86.53. After the transactions, the reporting person beneficially owned 84,024 shares, reported as direct ownership. The Form 4 was signed by an attorney-in-fact for the reporting person.
Ori Gutwerg, indicato come SVP, Generics presso ANI Pharmaceuticals (ANIP), ha comunicato la vendita di 5,873 azioni ordinarie ANI il 12 agosto 2025. Le azioni sono state vendute in pi霉 operazioni a prezzi compresi tra $86.50 e $86.79, con un prezzo medio ponderato dichiarato di $86.53. Dopo le transazioni, la persona che ha presentato la segnalazione deteneva beneficiariamente 84,024 azioni, indicate come propriet脿 diretta. Il Modulo 4 猫 stato firmato da un procuratore della persona segnalante.
Ori Gutwerg, registrado como SVP, Generics en ANI Pharmaceuticals (ANIP), inform贸 la venta de 5,873 acciones ordinarias de ANI el 12 de agosto de 2025. Las acciones se vendieron en varias operaciones a precios que oscilaron entre $86.50 y $86.79, con un precio medio ponderado divulgado de $86.53. Tras las transacciones, la persona informante pose铆a beneficiariamente 84,024 acciones, reportadas como propiedad directa. El Formulario 4 fue firmado por un apoderado de la persona informante.
鞓るΜ 甑快泴攴�電� ANI Pharmaceuticals(ANIP)鞐愳劀 SVP, Generics搿� 霌膘灛霅橃柎 鞛堨溂氅�, 2025雲� 8鞗� 12鞚�鞐� ANI 氤错喌欤� 5,873欤茧ゼ 毵る弰頄堧嫟瓿� 氤搓碃頄堨姷雼堧嫟. 頃措嫻 欤检嫕鞚� 鞐煬 瓯半灅搿� $86.50鞐愳劀 $86.79 靷澊鞚� 臧�瓴╈棎 毵る弰霅橃棃瓿�, 瓿奠嫓霅� 臧�欷戫弶攴� 毵る弰臧�瓴╈潃 $86.53鞓�鞀惦媹雼�. 瓯半灅 頉� 氤搓碃鞛愲姅 歆侅爲 氤挫湢搿� 氤搓碃霅� 84,024欤茧ゼ 鞁れ鞝侅溂搿� 氤挫湢頃橁碃 鞛堨棃鞀惦媹雼�. Form 4 靹滊電� 氤搓碃鞛愲ゼ 雽�鞁犿暅 雽�毽澑鞚� 靹滊獏頄堨姷雼堧嫟.
Ori Gutwerg, indiqu茅 comme SVP, Generics chez ANI Pharmaceuticals (ANIP), a d茅clar茅 la vente de 5,873 actions ordinaires ANI le 12 ao没t 2025. Les actions ont 茅t茅 vendues en plusieurs op茅rations 脿 des prix compris entre $86.50 et $86.79, avec un prix moyen pond茅r茅 d茅clar茅 de $86.53. Apr猫s ces op茅rations, la personne d茅clarante d茅tenait b茅n茅ficiairement 84,024 actions, d茅clar茅es comme propri茅t茅 directe. Le formulaire 4 a 茅t茅 sign茅 par un mandataire agissant pour la personne d茅clarante.
Ori Gutwerg, aufgef眉hrt als SVP, Generics bei ANI Pharmaceuticals (ANIP), meldete am 12. August 2025 den Verkauf von 5,873 Anteilen der ANI-Stammaktien. Die Aktien wurden in mehreren Trades zu Preisen zwischen $86.50 und $86.79 verkauft; der angegebene gewichtete Durchschnittspreis betrug $86.53. Nach den Transaktionen hielt die meldende Person wirtschaftlich 84,024 Aktien, ausgewiesen als unmittelbarer Besitz. Das Formular 4 wurde von einem Bevollm盲chtigten der meldenden Person unterzeichnet.
- Transparent disclosure of trade details including weighted average price and price range
- Post-sale ownership disclosed, showing continued direct stake of 84,024 shares
- Insider sale of 5,873 shares was executed, which reduces the reporting officer's holdings
Insights
TL;DR: A routine insider sale was reported; transaction details are transparent and show modest shares sold relative to total holdings.
The Form 4 documents a direct sale by an executive officer of 5,873 shares at a weighted average price of $86.53, executed in multiple trades priced between $86.50 and $86.79. The post-transaction beneficial ownership remains at 84,024 shares, indicating the sale reduced but did not eliminate the officer's stake. This filing provides clear execution prices and volume, which supports market transparency. The disclosure does not include any derivative activity or additional changes to ownership structure.
TL;DR: Filing is a standard Section 16 disclosure documenting an open-market sale; no governance red flags in the report itself.
The report identifies the reporting person as an officer (SVP, Generics) and shows a straightforward disposition of common stock through multiple trades, with a weighted average sale price disclosed and direct ownership remaining significant. The Form 4 is signed by an attorney-in-fact, which is a common execution method. There are no indications in this filing of stock-based compensation exercises, grants, or transfers to related parties that would raise governance concerns.
Ori Gutwerg, indicato come SVP, Generics presso ANI Pharmaceuticals (ANIP), ha comunicato la vendita di 5,873 azioni ordinarie ANI il 12 agosto 2025. Le azioni sono state vendute in pi霉 operazioni a prezzi compresi tra $86.50 e $86.79, con un prezzo medio ponderato dichiarato di $86.53. Dopo le transazioni, la persona che ha presentato la segnalazione deteneva beneficiariamente 84,024 azioni, indicate come propriet脿 diretta. Il Modulo 4 猫 stato firmato da un procuratore della persona segnalante.
Ori Gutwerg, registrado como SVP, Generics en ANI Pharmaceuticals (ANIP), inform贸 la venta de 5,873 acciones ordinarias de ANI el 12 de agosto de 2025. Las acciones se vendieron en varias operaciones a precios que oscilaron entre $86.50 y $86.79, con un precio medio ponderado divulgado de $86.53. Tras las transacciones, la persona informante pose铆a beneficiariamente 84,024 acciones, reportadas como propiedad directa. El Formulario 4 fue firmado por un apoderado de la persona informante.
鞓るΜ 甑快泴攴�電� ANI Pharmaceuticals(ANIP)鞐愳劀 SVP, Generics搿� 霌膘灛霅橃柎 鞛堨溂氅�, 2025雲� 8鞗� 12鞚�鞐� ANI 氤错喌欤� 5,873欤茧ゼ 毵る弰頄堧嫟瓿� 氤搓碃頄堨姷雼堧嫟. 頃措嫻 欤检嫕鞚� 鞐煬 瓯半灅搿� $86.50鞐愳劀 $86.79 靷澊鞚� 臧�瓴╈棎 毵る弰霅橃棃瓿�, 瓿奠嫓霅� 臧�欷戫弶攴� 毵る弰臧�瓴╈潃 $86.53鞓�鞀惦媹雼�. 瓯半灅 頉� 氤搓碃鞛愲姅 歆侅爲 氤挫湢搿� 氤搓碃霅� 84,024欤茧ゼ 鞁れ鞝侅溂搿� 氤挫湢頃橁碃 鞛堨棃鞀惦媹雼�. Form 4 靹滊電� 氤搓碃鞛愲ゼ 雽�鞁犿暅 雽�毽澑鞚� 靹滊獏頄堨姷雼堧嫟.
Ori Gutwerg, indiqu茅 comme SVP, Generics chez ANI Pharmaceuticals (ANIP), a d茅clar茅 la vente de 5,873 actions ordinaires ANI le 12 ao没t 2025. Les actions ont 茅t茅 vendues en plusieurs op茅rations 脿 des prix compris entre $86.50 et $86.79, avec un prix moyen pond茅r茅 d茅clar茅 de $86.53. Apr猫s ces op茅rations, la personne d茅clarante d茅tenait b茅n茅ficiairement 84,024 actions, d茅clar茅es comme propri茅t茅 directe. Le formulaire 4 a 茅t茅 sign茅 par un mandataire agissant pour la personne d茅clarante.
Ori Gutwerg, aufgef眉hrt als SVP, Generics bei ANI Pharmaceuticals (ANIP), meldete am 12. August 2025 den Verkauf von 5,873 Anteilen der ANI-Stammaktien. Die Aktien wurden in mehreren Trades zu Preisen zwischen $86.50 und $86.79 verkauft; der angegebene gewichtete Durchschnittspreis betrug $86.53. Nach den Transaktionen hielt die meldende Person wirtschaftlich 84,024 Aktien, ausgewiesen als unmittelbarer Besitz. Das Formular 4 wurde von einem Bevollm盲chtigten der meldenden Person unterzeichnet.
FAQ
What transaction did Ori Gutwerg report on the ANIP Form 4?
At what price were the ANIP shares sold in this Form 4?
How many ANIP shares does the reporting person own after the sale?
What is the reporting person鈥檚 role at ANI Pharmaceuticals?
Does the Form 4 show any derivative transactions for ANIP by the reporting person?
